Publications by authors named "E de Jongh"
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014).
Eur J Cancer
January 2025
Purpose: Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages.
View Article and Find Full Text PDFArticle Synopsis
- The study highlights that five-year survivors of diffuse large B-cell lymphoma (DLBCL) are at a higher risk of developing subsequent malignant neoplasms (SMNs), particularly among younger patients and those treated with higher doses of certain chemotherapy drugs.
- After a median follow-up of 13.8 years, 321 out of 2373 survivors developed SMNs, with significant increases noted for lung and gastrointestinal cancers.
- The research indicates that treatment including rituximab may lower the risk of certain cancers, underscoring the importance of long-term monitoring of DLBCL survivors and the need for further studies to assess risks associated with newer treatments.
Patients with MYC rearranged (MYC-R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Previously, we demonstrated in a single-arm phase II trial (HOVON-130) that addition of lenalidomide to R-CHOP (R2CHOP) is well-tolerated and yields similar complete metabolic remission rates as more intensive chemotherapy regimens in literature. In parallel with this single-arm interventional trial, a prospective observational screening cohort (HOVON-900) was open in which we identified all newly diagnosed MYC-R DLBCL patients in the Netherlands.
View Article and Find Full Text PDFBackground And Objective: Multiple myeloma is an incurable disease with a considerable illness and treatment burden, which negatively impacts patients' quality of life. This study aimed to evaluate the implementation of multiple myeloma care in five Dutch hospitals, related to the three objectives of outcome-driven care, which are defined as (1) providing information for shared decision making in individual patient care, (2) supporting the learning capacity of healthcare professionals and healthcare institutions through benchmarking and (3) developing outcome-driven and patient-centred contracting by health insurers.
Methods: In this qualitative study, semi-structured interviews about experiences with patient-reported outcomes were conducted with patients, healthcare professionals and other stakeholders 2 years after implementation.